Pharma BD Deal Intelligence

Merck & Co. Inc. / Immune Design Corp.

2019 · Acquisition/Merger · $300M · Complete

Announcement Sentiment

Strongly positive

Merck agreed to acquire Immune Design for $5.85/share, or approximately $300 million, to add the GLAAS and ZVex platforms used to develop cancer vaccines and immunotherapies. Closed Q2 2019.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Mar 18, 2019
Closed Apr 02, 2019
Deal value $300M
Deal type Acquisition/Merger
Therapeutic area Cancer vaccines, infectious diseases
Indications Cancer vaccines, infectious diseases
Key assets GLAAS and ZVex platforms
Mechanism TLR4 agonist (GLA) and dendritic-cell-targeting lentiviral vectors

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals